Search Results 311-320 of 18470 for Relapse

  1. Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139) - Mayo Clinic

    Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem ...

  2. A Study Of ABBV-383 With Relapsed Refractory Waldenström Macroglobulinemia - Mayo Clinic

    The purpose of this study is to determine the safety, maximum tolerated dose (MTD) and RP2D of ABBV-383 monotherapy for patients with RRWM and to determine VGPR ...

  3. Study of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140) - Mayo Clinic

    Study of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140) · Overview · Participation eligibility · Participating Mayo ...

  4. Rectal prolapse - Symptoms and causes - Mayo Clinic

    Symptoms · You cannot control your bowel movements, known as fecal incontinence. · Constipation or loose stools. · Leaking blood or mucus from the rectum. · Feeling ...

  5. GB5121 in Adult Subjects With Relapsed/Refractory CNS Lymphoma - Mayo Clinic

    GB5121 in Adult Subjects With Relapsed/Refractory CNS Lymphoma · Overview · Participation eligibility · Participating Mayo Clinic locations · More information ...

  6. A Study to Evaluate ION251 to Treat Patients with Relapsed/Refractory Multiple Myleoma - Mayo Clinic

    The purpose of this study is to determine the maximum-tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of ION251 in patients with relapsed/refractory ...

  7. Drug Addiction (Substance Use Disorder) Clinical Trials - Mayo Clinic Research

    ... relapses or slips. A Study to Analyse the Genetic Makeup of Those with ... Relapse in Subjects with Substance Use Disorders Rochester, MN. Impulsivity ...

  8. A Study Of GC012F (AZD0120), A CAR T Therapy Targeting CD19 And BCMA In Subjects With Relapsed/Refractory Multiple Myeloma - Mayo Clinic

    This trial is a phase 1b/2, open-label, multicenter study of GC012F (AZD0120), a CD19/BCMA dual CART-cell therapy, in adult subjects with relapsed/refractory ...

  9. Vitamin D and MS: Is there any connection? - Mayo Clinic

    Taking vitamin D also may lower the risk of relapse and may decrease new scarring in the nervous system. New scarring can be seen on MRI and are known as ...

  10. Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma - Mayo Clinic

    About this study. This phase II trial studies how well nivolumab works in treating patients with peripheral T-cell lymphoma that has come back after a ...